PPT-Cardiovascular Disease in Women: Update on Menopausal

Hormone Therapy and Selective Estrogen Receptor Modulators SERMs 2 Hormone Replacement Therapy RiskBenefit Balance 1960s1990s Risks Benefits CHD Osteoporosis Vasomotor Symptoms. Prevention & Treatment. . in Women: Update on the . 2011 American Heart Association Guidelines. Objectives. Discuss strategies to assess and stratify women into high risk, at risk, and ideal health categories for cardiovascular disease (CVD). Donna Locher CNM PhD. Columbus Ohio. WHI data & post WHI analysis risk/benefits for HRT. Symptom management for menopausal women for hot flashes, vaginal dryness. . . Hrt. . non . HRt. Help clinician beginning doses/regimen for starting HRT. C. ardiovascular Disease. Anthony Camuglia MBBS(. HonsI. ), FRACP. Interventional and General Cardiologist. Mater Hospitals, Brisbane, Australia. Princess Alexandra Hospital, Brisbane, Australia. Senior Lecturer, University of Queensland, Australia. In the Classroom. September/October 2013 issue of . Radiologic Technology. Instructions:. This presentation provides a framework for educators and students to use Directed Reading content published in . E. . Thomas-Eapen, . MD, FAAFP. Assistant Professor of Family Medicine. University of Kentucky . October. 2017. Objectives. Statistics of heart disease in women. Gender variations of the disease in women. 1intermediate vascular traits and all-cause mortality a systematic review and meta-analysis of observational studiesTaulant Muka MD PhD1 Clare Oliver-Williams PhD2 Setor Kunutsor MD PhD2 Joop SE Laven OVERVIEWis the No 1 cause of death in American women claiming over 400000 lives each year or one death every 80 seconds1CVD kills approximately the same number of women as all forms of cancer chronic 178 a multinational, prospective, community-based survey Introduction Women may experience different symptoms attributed to menopause based on their stage of transition [1-4] , and not all women ex ADAPTED FROM:. . The 2023 Scientific Statement From the AHA:. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic Syndrome. Definition of . Cardiovascular-Kidney-Metabolic Syndrome (CKM). Claire S. . Duvernoy. , MD FACC. Female Specific. concerns. U.S. CVD Deaths. CVD. deaths. Salim S. Virani. Circulation. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association, Volume: 141, Issue: 9, Pages: e139-e596.. Minoo. . Yaghmaei. NIDDM. obese and non obese women with PCOS. Hyper . insulinaemia. . and insulin resistance are characteristic features. β. – cell dysfunction. Obesity. Insulin resistance impaired glucose tolerance & non . A Scientific Statement From the AHA. Definition of . Cardiovascular-Kidney-Metabolic Syndrome (CKM). A systemic disorder characterized by pathophysiologic interactions among metabolic risk factors, chronic kidney disease, and the cardiovascular system, leading to multi-organ dysfunction and a high rate of adverse cardiovascular outcomes.. GGC MCN meeting 5. th. February 2019. John R Petrie. Professor of Diabetic Medicine. University of Glasgow, UK. Advisory and Consultancy Work:. Novo Nordisk, Sanofi-Aventis, Biocon, Astra Zeneca, . Servier. www.amwa-doc.org. WomenHeart. . The National Coalition for Women with Heart Disease. www.womenheart.org. Centers for Disease Control and Prevention. www.cdc.gov. Women’s . HeartHealth. at Stanford.